Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Shattuck Labs, Inc. (NASDAQ: STTK) has released its financial results for the fourth quarter and full year ended December 31, 2025. The company also provided updates on its clinical pipeline, recent business developments, and capital markets activity. These disclosures are highly relevant to shareholders and may impact share value.
Key Highlights
- Phase 1 Clinical Trial Progress: Shattuck’s Phase 1 clinical trial for SL-325 remains ongoing, with data expected in the second quarter of 2026. The company continues to prioritize this program, which could provide significant value inflection upon positive clinical readouts.
- Upcoming Investor Conference: Shattuck announced its participation in the Leerink Global Healthcare Conference 2026 (Miami, FL) from March 8-11, 2026. Dr. Taylor Schreiber, CEO, will present and participate in one-on-one meetings, potentially increasing visibility and engagement with institutional investors.
- Capital Markets Activity: In Q1 2026, Shattuck raised gross proceeds of \$21.4 million through its at-the-market (ATM) equity offering facility. As a result, accounts advised by T. Rowe Price Investment Management, Inc. have reported beneficial ownership of more than 10% of the company’s outstanding common stock. This significant increase in institutional ownership is a notable development for shareholders, as it may impact liquidity and the company’s institutional profile.
Financial Results
- Net Loss Improvement: Net loss for Q4 2025 was \$12.6 million (\$0.12 per basic and diluted share), improved from a net loss of \$18.7 million (\$0.37 per share) in Q4 2024. For the full year 2025, net loss was \$48.8 million (\$0.70 per share), a substantial reduction from \$75.4 million (\$1.49 per share) in 2024. This improvement is primarily attributed to decreased compensation and related expenses following workforce reductions in 2024, as well as lower legal fees.
- Revenue: The company reported no product revenue for Q4 2025 and FY2025. Collaboration revenue in previous periods was primarily related to prior agreements, and no new collaboration revenue was recognized in the recent reporting periods.
- R&D and Operating Expenses: The company continues to manage its operating costs, with research and development expenses being the primary expenditure, reflecting ongoing investment in its clinical programs.
- Cash Position: As of December 31, 2025, Shattuck reported cash and cash equivalents of \$57.4 million and investments of \$23.9 million, totaling approximately \$81.3 million in liquid assets. The company maintains a strong balance sheet, with total stockholders’ equity of \$82.4 million.
Forward-Looking Guidance and Risks
- Upcoming Data Readout: The anticipated Phase 1 data for SL-325 in Q2 2026 is a crucial upcoming catalyst that could significantly affect the company’s valuation depending on clinical outcomes.
- Institutional Ownership: The increase in ownership by T. Rowe Price-advised accounts to above 10% of outstanding shares is a strong vote of confidence but also means that future trading activity by this holder could influence share price volatility.
- Liquidity and Capital Resources: With over \$81 million in liquid assets following the ATM offering, Shattuck is well-capitalized to continue funding its operations and clinical programs in the near-term.
- Operational and Regulatory Risks: Investors should note that Shattuck’s forward-looking statements are subject to significant risks, including the unpredictability of clinical development, regulatory outcomes, and macroeconomic conditions. The actual results may differ materially from projections.
Other Notable Disclosures
- Shattuck reiterated its intention to use the investor relations section of its website to disclose material non-public information and to comply with Regulation FD.
- The company’s Chief Executive Officer, Dr. Taylor Schreiber, signed the report, underscoring management’s commitment to transparency.
Conclusion
Shattuck Labs’ latest financial results and business developments provide a mixed picture—while the company continues to operate at a net loss, the improvements compared to prior periods, strengthened balance sheet, and the involvement of a major institutional investor are positive indicators. However, the company’s future valuation is likely to be highly sensitive to upcoming clinical data and ongoing capital market dynamics.
Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as outlined by Shattuck Labs, Inc. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The author and publisher are not responsible for any losses arising from reliance on this information.
View Shattuck Labs, Inc. Historical chart here
